Simultaneous Determination of Antiretroviral Zidovudine, Lamivudine and Efavirenz by RP HPLC-DAD

Mônica F. de L.R. SOARES 1, José L. SOARES-SOBRINHO 1, Keyla E. R. da SILVA 2, Larissa A. ROLIM 2, Lariza D.S. ALVES 2 & Pedro J. ROLIM-NETO 2*  

1 Core of Pharmaceutical Technology - NTF. Federal University of Piauí - UFPI.  
Campus Universitário Ministro Petrônio Portella, s/n, Ininga, 64.049-550. Teresina – PI, Brazil.  
2 Laboratory of Medicines Technology - LTM, Department of Pharmaceutical Sciences, Federal University of Pernambuco – UFPE. Arthur de Sá, s/n. Cidade Universitária, 50740-521. Recife – PE, Brazil.  

SUMMARY. A reverse phase high-performance liquid chromatography-photodiode array detector (RP HPLC-DAD) method for simultaneous determination of lamivudine (3TC), zidovudine (AZT), two nucleoside reverse transcriptase inhibitors, and efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, in tablets is described. The drugs separation was performed on a C18 column (250 x 4.6 mm, 5 μm - Phenomenex®), through a mobile phase drag composed by a binary gradient of acetonitrile and water HPLC grade. The drugs detection was performed at 248 nm, resulting in a 14 min chromatographic run. The samples were prepared by crushing tablets, weighing powder, diluting it by a 10 min sonication and filtrating solution, resulting in samples with final concentration of 20, 40 e 40 μg.mL–1 of 3TC, AZT and EFV, respectively. The method was adequate for quality control purposes and was validated following the ICH guidelines.